NCDB analysis of de-escalation of postmastectomy irridiation in HR-positive breast cancer with one to three positive nodes
Prof. Suzanne Klimberg
The 21-gene recurrence score (RS) is used to predicte benefit from chemotherapy in hormone receptor-positive breast cancer with one to three positive lymph nodes. RS also is prognostic for both systemic and locoregional recurrence in tamoxifen-treated patients. Analysis of the National Cancer Database found that among women ≤ 75 years of age with met HR-positive HER2-negative T1-3 N1 M0 breast cancer and a 21-gene recurrence score ≤ 25, omission of post-mastectomy radiation therapy (PMRT) had no impact on overall survival. The authors conclude that these results suggest that RS may be utilized in the individualized decision making on PMRT.
